Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration

Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration

Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective e...

Full description

Bibliographic Details
Main Authors: Benjamin Ng, Hema Kolli, Naduviledeth Ajith Kumar, Matthew Azzopardi, Abison Logeswaran, Julius Buensalido, Bushra Mushtaq, Randhir Chavan, Yu Jeat Chong
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Life
Subjects:
faricimab
neovascular age-related macular degeneration
anti-VEGF
Ang-2
Online Access:https://www.mdpi.com/2075-1729/14/2/193

Internet

https://www.mdpi.com/2075-1729/14/2/193

Similar Items